Stephane Bancel
At a glance: Stephane Bancel is CEO at Moderna (MRNA). Their latest SEC Form 4, filed Aug 7, 2026, reported a sale of $8.3M. On file: 0 purchase lines ($0) and 4 sale lines ($28.7M).
Disclosed holdings: about $1.24B of MRNA stock: 6,187,791 shares reported on their latest Form 4 (filed Aug 7, 2026), valued at the Nov 19, 2026 close of $200.20. This counts only MRNA shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
CEO at Moderna, Inc. (MRNA)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Stephane Bancel's InsiderPrint
5 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 4 times a year, typically $7.1M a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (1)
- Dent inward: a sale (4)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Nicholas A.J. BotwoodHead Of R&D, Cmo · SNDX · 96% match
- Ryan CorbettCFO · MP · 95% match
- Clarence L. GrangerDirector · UCTT · 95% match
- Lara PoloniPresident · ACM · 95% match
- James C. Fish Jr.Director · CAT · 95% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2025
From the SEC's insider data sets: each open-market buy by Stephane Bancel, matched to how the stock did over the next 90 days against the S&P 500.
0 of 1 buy beat the S&P 500 (0%), median -14.0% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| MRNA | Mar 4, 2025 | -14.0% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 7SEC | MRNAModerna, Inc. | Sell Plan | 147,4736,539,564 held (−2%) | $56.21 | $8.3M | +256.2% |
| Aug 7SEC | MRNAModerna, Inc. | Sell Plan | 124,8386,414,726 held (−2%) | $56.96 | $7.1M | +251.5% |
| Aug 7SEC | MRNAModerna, Inc. | Sell Plan | 39,8916,374,835 held (−1%) | $58.12 | $2.3M | +244.5% |
| Aug 7SEC | MRNAModerna, Inc. | Sell Plan | 187,0446,187,791 held (−3%) | $58.79 | $11.0M | +240.5% |
- Sell
CEO Stephane Bancel sold $8.3M of MRNA at $56.21 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Stephane Bancel sold $7.1M of MRNA at $56.96 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Stephane Bancel sold $2.3M of MRNA at $58.12 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Stephane Bancel sold $11.0M of MRNA at $58.79 — pre-scheduled 10b5-1 plan sale.
Follow Stephane Bancel
Get one email when Stephane Bancel files a new purchase or sale. Free.
At most one email a day about Stephane Bancel, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.